ReviewCurrent HIV/AIDS reports2020
Immunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIV.
Review in Current HIV/AIDS reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Effects and safety of Chinese herbal medicine on inflammatory biomarkers in cardiovascular diseases: A systematic review and meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2022Pooled it
- Thromboinflammatory biomarkers and thrombotic risk in virologic failure and drug-resistant HIV: Emerging roles of d-dimer, fibrinogen, and coagulation dysregulation.Journal of thrombosis and thrombolysis · 2026Review
- Neuroinflammatory crosstalk between microglia and astrocytes increases viral replication in an iPSC-derived model of CNS HIV infection.Scientific reports · 2026Article
- Unsupervised proteomic stratification of people living with HIV reveals inflammatory biotypes beyond conventional clinical classifications.Frontiers in immunology · 2026Article
- Genetic and molecular landscape of comorbidities in people living with HIV.Nature medicine · 2025Article
- Neuroinflammatory crosstalk between microglia and astrocytes increases viral replication in an iPSC-derived model of CNS HIV infection.bioRxiv : the preprint server for biology · 2025Article
- CD24-Fc resolves inflammation and enhances anti-HIV CD8 T cells with polyfunctionality during HIV-1 infection under cART.PLoS pathogens · 2025Article
- The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy.Open forum infectious diseases · 2025Article
- Precision Phenotyping of Heart Failure in People with HIV: Early Insights and Challenges.Current heart failure reports · 2024Review
- Distinct Effects of Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors on Soluble Biomarkers in Blood and Cerebrospinal Fluid of People With HIV.The Journal of infectious diseases · 2024Article
- Metabolic and inflammatory perturbation of diabetes associated gut dysbiosis in people living with and without HIV infection.Genome medicine · 2024Article
- Brief communications: changes in inflammatory biomarkers and lipid profiles after switching to long-acting cabotegravir plus rilpivirine.AIDS research and therapy · 2024Article
- Roadmap for Achieving Universal Antiretroviral Treatment.Annual review of pharmacology and toxicology · 2023Review
- The microbiota as a modulator of mucosal inflammation and HIV/HPV pathogenesis: From association to causation.Frontiers in immunology · 2023Review
- Estrogen May Enhance Toll-Like Receptor 4-Induced Inflammatory Pathways in People With HIV: Implications for Transgender Women on Hormone Therapy.Frontiers in immunology · 2022Article
- Childhood sexual abuse history amplifies the link between disease burden and inflammation among older adults with HIV.Brain, behavior, & immunity - health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewIn this review, we will discuss treatment interventions targeting drivers of immune activation and chronic inflammation in PWH. RECENT
findingsPotential treatment strategies to prevent the progression of comorbidities in PWH have been identified. These studies include, among others, the use of statins to modulate lipid alterations and subsequent innate immune receptor activation, probiotics to restore healthy gut microbiota and reduce microbial translocation, hydroxychloroquine to reduce immune activation by altering Toll-like receptors function and expression, and canakinumab to block the action of a major pro-inflammatory cytokine IL-1β. Although many of the treatment strategies discussed here show promise, due to the complex nature of chronic inflammation and comorbidities in PWH, larger clinical studies are needed to understand and target the prominent drivers and inflammatory cascades underlying these end-organ diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.